Effect of amphiphilic surfactant agents on the gastrointestinal absorption of albendazole in cattle
- 19 February 2003
- journal article
- research article
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 24 (3) , 95-103
Abstract
Albendazole (ABZ) is a widely used broad‐spectrum benzimidazole (BZD) anthelmintic. Low hydrosolubility and poor/erratic gastrointestinal (GI) absorption play against the systemic availability and resultant clinical efficacy of BZD compounds. Different strategies are currently investigated to improve their bioavailability and efficacy in different animal species and humans. Surfactant agents facilitate dissolution of lipophilic drugs and increase membrane permeability. The influence of amphiphilic surfactants on the pattern of absorption and systemic availability of ABZ and its metabolites in cattle was characterized in the current trial. Twenty (20) parasite‐free Holstein calves (100–120 kg) were randomly allocated into four groups and treated intraruminally (10 mg/kg) using one of the following ABZ suspensions: control without surfactant (75/25 dimetyl sulphoxide/saline solution) (group A), 5 mM sodium taurocholate (STC) in saline solution (group B), 8.27 mM sodium lauryl sulphate (SLS) in saline solution (group C) and a commercial formulation (Valbazen®, Pfizer Inc. SA) (group D). Jugular blood samples were taken over 72 h post‐treatment and plasma analysed by HPLC. Albendazole sulphoxide (ABZSO) and sulphone were the metabolites found in plasma. STC did not affect ABZ absorption while increased ABZSO peak plasma concentration (Cmax) (158% higher, P<0.001) was observed following co‐administration of ABZ plus SLS, compared to the control group without surfactant. ABZSO plasma availability was significantly greater after the ABZ–SLS (164%) co‐administration compared to that obtained in the control group without surfactant. A similar ABZSO plasma availability was obtained following the treatments with the ABZ‐SLS and the commercially available formulation. SLS‐mediated enhanced dissolution and absorption of ABZ accounted for the observed increased systemic availability of the active ABZSO metabolite in cattle. These results should be considered among strategies to improve the use of BZD anthelmintics. Copyright © 2003 John Wiley & Sons, Ltd.Keywords
This publication has 38 references indexed in Scilit:
- In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazoleCancer Letters, 2001
- Drug treatment of microsporidiosisDrug Resistance Updates, 2000
- Ricobendazole kinetics and availability following subcutaneous administration of a novel injectable formulation to calvesResearch in Veterinary Science, 1998
- Influence of surfactants on oral bioavailability of albendazole based on the formation of the sulphoxide metabolites in ratsBiopharmaceutics & Drug Disposition, 1998
- Development of an injectable formulation of albendazole and in vivo evaluation of its efficacy against Echinococcus multilocularis metacestodeInternational Journal for Parasitology, 1995
- The effect of level of feed intake on the pharmacokinetic disposition of oxfendazole in sheepInternational Journal for Parasitology, 1995
- Comparative effects of anionic, natural bile acid surfactants and mixed micelles on the intestinal absorption of the anthelmintic albendazoleInternational Journal of Pharmaceutics, 1993
- Effect of surfactants on Albendazole absorptionJournal of Pharmaceutical and Biomedical Analysis, 1991
- The benzimidazole anthelmintic agents‐a reviewJournal of Veterinary Pharmacology and Therapeutics, 1990
- Pharmacokinetic behaviour and anthelmintic efficacy of 1-n-butyl carbamoyl oxfendazole given by intramuscular injectionVeterinary Research Communications, 1983